These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 34371133)

  • 41. COVID-19 associated mucormycosis - An emerging threat.
    Chao CM; Lai CC; Yu WL
    J Microbiol Immunol Infect; 2022 Apr; 55(2):183-190. PubMed ID: 35074291
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Pediatric rhino-orbital mucormycosis. First peruvian case in times of the COVID-19 pandemic].
    Meregildo-Rodriguez ED; Espino-Saavedra WG
    Rev Peru Med Exp Salud Publica; 2021; 38(3):472-473. PubMed ID: 34932752
    [No Abstract]   [Full Text] [Related]  

  • 43. Mucormycosis: An opportunistic pathogen during COVID-19.
    Mahalaxmi I; Jayaramayya K; Venkatesan D; Subramaniam MD; Renu K; Vijayakumar P; Narayanasamy A; Gopalakrishnan AV; Kumar NS; Sivaprakash P; Sambasiva Rao KRS; Vellingiri B
    Environ Res; 2021 Oct; 201():111643. PubMed ID: 34237335
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overdiagnosis and overtreatment during the covid-19 pandemic.
    Devnani M
    BMJ; 2021 Nov; 375():n2688. PubMed ID: 34759004
    [No Abstract]   [Full Text] [Related]  

  • 45. Risk factors for palatal and orbital involvement in mucormycosis epidemic-Report of a center in India.
    Bhat VK; Bongale KR; Basti SP; Gadag RP; Kizhakkilottu N; Sebastian E; Gopalegowda MK; Thammaiah P
    Am J Otolaryngol; 2022; 43(2):103371. PubMed ID: 34995965
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diabetes, COVID 19 and mucormycosis: Clinical spectrum and outcome in a tertiary care medical center in Western India.
    Mishra Y; Prashar M; Sharma D; Akash ; Kumar VP; Tilak TVSVGK
    Diabetes Metab Syndr; 2021; 15(4):102196. PubMed ID: 34246939
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Five probable factors responsible for the COVID-associated mucormycosis outbreak in India.
    Ravindra K; Ahlawat A
    Int J Infect Dis; 2021 Nov; 112():278-280. PubMed ID: 34592439
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India.
    Singh AK; Singh R; Joshi SR; Misra A
    Diabetes Metab Syndr; 2021; 15(4):102146. PubMed ID: 34192610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serious health threat of mucormycosis during the ongoing COVID-19 pandemic: what dermatologists need to know in this regard.
    Hatami P; Balighi K; Nicknam Asl H; Aryanian Z
    Int J Dermatol; 2022 Aug; 61(8):979-981. PubMed ID: 35094397
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Past, Present and Future of COVID-19 Associated Mucormycosis: A Rapid Review.
    Sarfraz Z; Sarfraz A; Jaiswal V; Poudel S; Bano S; Hanif M; Singh Shrestha P; Sarfraz M; Michel G; Cherrez-Ojeda I
    J Prim Care Community Health; 2022; 13():21501319221099476. PubMed ID: 35587142
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Can low-dose radiation therapy reduce the risk of mucormycosis in COVID-19 patients?
    Sharma DN; Welsh J; Kumar R
    J Cancer Res Ther; 2021; 17(6):1294-1296. PubMed ID: 34916356
    [No Abstract]   [Full Text] [Related]  

  • 52. Mucormycosis in COVID-19 patients.
    Sundaram N; Bhende T; Yashwant R; Jadhav S; Jain A
    Indian J Ophthalmol; 2021 Dec; 69(12):3728-3733. PubMed ID: 34827032
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave?
    Raut A; Huy NT
    Lancet Respir Med; 2021 Aug; 9(8):e77. PubMed ID: 34090607
    [No Abstract]   [Full Text] [Related]  

  • 54. Mucormycosis in COVID-19 patients: predisposing factors, prevention and management.
    Rudrabhatla PK; Reghukumar A; Thomas SV
    Acta Neurol Belg; 2022 Apr; 122(2):273-280. PubMed ID: 34820787
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mass urine sugar testing to tackle post-COVID mucormycosis epidemic in India-MUSTARD concept.
    Garg P; Mittal S
    Diabetes Metab Syndr; 2021; 15(4):102177. PubMed ID: 34198108
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SARS-CoV-2 (COVID-19) and the lessons learned from global pandemic.
    Acquilla S; Sibal B; Shukla H; Mathews S; Rai GK; Lakhanpaul M
    Indian J Public Health; 2021; 65(3):215-217. PubMed ID: 34558480
    [No Abstract]   [Full Text] [Related]  

  • 57. Rampant Increase in Cases of Mucormycosis in India and Pakistan: A Serious Cause for Concern during the Ongoing COVID-19 Pandemic.
    Ghazi BK; Rackimuthu S; Wara UU; Mohan A; Khawaja UA; Ahmad S; Ahmad S; Hasan MM; Dos Santos Costa AC; Ahmad S; Essar MY
    Am J Trop Med Hyg; 2021 Aug; 105(5):1144-1147. PubMed ID: 34460426
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mucor in a Viral Land: A Tale of Two Pathogens.
    Sen M; Lahane S; Lahane TP; Parekh R; Honavar SG
    Indian J Ophthalmol; 2021 Feb; 69(2):244-252. PubMed ID: 33463566
    [TBL] [Abstract][Full Text] [Related]  

  • 59. COVID Associated Mucormycosis: A Study on the Spectrum of Clinical, Biochemical and Radiological Findings in A Series of Ten Patients.
    Pal P; Chatterjee N; Ghosh S; Ray BK; Mukhopadhyay P; Bhunia K; Srivastava SR; Adhikari S; Barman D; Banerjee B; Mukhopadhyay M; Pal J
    J Assoc Physicians India; 2021 Oct; 69(10):11-12. PubMed ID: 34781648
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Using artificial intelligence-based models to predict the risk of mucormycosis among COVID-19 survivors: An experience from a public hospital in India.
    Syed-Abdul S; Babu AS; Bellamkonda RS; Itumalla R; Acharyulu G; Krishnamurthy S; Ramana YVS; Mogilicharla N; Malwade S; Li YC
    J Infect; 2022 Mar; 84(3):351-354. PubMed ID: 34953910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.